about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

RA Cap­i­tal, Hill­house join $310M rush to back Ever­est's climb to com­mer­cial heights in Chi­na

5 years ago
Financing
China

Covid-19 roundup: Ab­b­Vie jumps in­to Covid-19 an­ti­body hunt; As­traZeneca shoots for 2B dos­es of Ox­ford vac­cine — ...

5 years ago
Coronavirus

Covid-19 roundup: Mod­er­na read­ies to en­ter PhI­II in Ju­ly, As­traZeneca not far be­hind; EU ready to ne­go­ti­ate vac­cine ...

5 years ago
Coronavirus

New safe­ty da­ta ex­pose po­ten­tial weak­ness as Pfiz­er's abroc­i­tinib takes on Dupix­ent in eczema

5 years ago
R&D

José Basel­ga finds promise in new class of RNA-mod­i­fy­ing can­cer tar­gets, lock­ing in 3 pre­clin­i­cal pro­grams with $55M

5 years ago
Deals

Bull­ish biotech mar­ket pro­pels Pli­ant to $144M IPO — as No­var­tis pro­vides a $10M boost

5 years ago
Financing

As NL­RP3 play­ers head for first clin­i­cal face-off, No­vo, Sanofi fu­el trans-At­lantic con­tender with $55M

5 years ago
Financing

Gilead woos fil­go­tinib clin­i­cal in­ves­ti­ga­tor from Stan­ford to lead the charge on NASH, in­flam­ma­to­ry dis­eases

5 years ago
People

Hill­house re­casts spot­light on Chi­na's biotech scene with $160M round for Shang­hai-based an­ti­body mak­er

5 years ago
Financing
China

Spark touts an­i­mal da­ta for a so­lu­tion to AAV gene ther­a­py's an­ti­body prob­lem

5 years ago
Discovery
Cell/Gene Tx

Ab­b­Vie grabs SHP2 in­hibitors from Chi­na's Ja­co­bio; Chi-Med set on US fil­ing of su­r­u­fa­tinib

5 years ago
News Briefing

Covid-19 roundup: Did in­sid­ers cash in on pos­i­tive news re­port about Gilead be­fore pub­li­ca­tion?

5 years ago
Coronavirus

Ear­ly sur­vival da­ta boost Zio­phar­m's 'con­trolled IL-12' im­munother­a­py for glioblas­toma

5 years ago
R&D
Cell/Gene Tx

Pfiz­er, Mer­ck KGaA ce­ment Baven­cio blad­der can­cer win with OS da­ta — while carv­ing an­oth­er niche in rare can­cer

5 years ago
R&D
Pharma

In for the long vac­cine game, Mer­ck buys in­to patch de­liv­ery tech with pan­dem­ic po­ten­tial

5 years ago
R&D

Covid-19 roundup: FDA's Stephen Hahn per­son­al­ly helped a doc­tor set up hy­drox­y­chloro­quine tri­al — re­port

5 years ago
Coronavirus

For a post-Soliris world, At­las-backed Q32 Bio out­lines $46M next-gen com­ple­ment play

5 years ago
Financing
Startups

Bris­tol My­ers Squibb fi­nal­ly gets in the front­line NSCLC game dom­i­nat­ed by Mer­ck, adding a sec­ond Op­di­vo/Yer­voy-based ...

5 years ago
Pharma
FDA+

In lat­est can­cer deal, Bris­tol My­ers Squib­b's new BD chief bets $65M in search for more tar­gets like PARP

5 years ago
Deals

Ex-Ax­o­vant crew at Arvelle ups Se­ries A haul, de­ploy­ing $200M-plus to com­mer­cial­ize epilep­sy drug in Eu­rope

5 years ago
Financing

Covid-19 roundup: Jun­shi, Eli Lil­ly ready to launch Covid-19 an­ti­body tri­al; Janet Wood­cock steps aside — for now ...

5 years ago
Coronavirus

Re­struc­tured Melin­ta now wants to buy fel­low an­tibi­ot­ic mak­er Tetraphase; TA As­so­ciates mulls $500M deal for a stake ...

5 years ago
News Briefing

GSK inks $231M man­u­fac­tur­ing deal as Hal Bar­ron an­tic­i­pates fruit­ful year for pruned R&D group

5 years ago
Outsourcing

Covid-19 roundup: CanSi­no beats Mod­er­na to pub­li­ca­tion of first-in-hu­man da­ta for a coro­n­avirus vac­cine

5 years ago
Coronavirus
First page Previous page 74757677787980 Next page Last page
A service from the Financial Times